Cite
Bitting RL, Healy P, George DJ, et al. Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. Eur Urol Oncol. 2020;doi: 10.1016/j.euo.2020.01.005.
Bitting, R. L., Healy, P., George, D. J., Anand, M., Kim, S., Mayer, T., Winters, C., Riggan, C., Rasmussen, J., Wilder, R., Stein, M., Frizzell, B., Harrison, M. R., Zhang, T., Lee, W. R., Wu, Y., Koontz, B. F., & Armstrong, A. J. (2020). Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. European urology oncology, . https://doi.org/10.1016/j.euo.2020.01.005
Bitting, Rhonda L, et al. "Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial." European urology oncology vol. (2020). doi: https://doi.org/10.1016/j.euo.2020.01.005
Bitting RL, Healy P, George DJ, Anand M, Kim S, Mayer T, Winters C, Riggan C, Rasmussen J, Wilder R, Stein M, Frizzell B, Harrison MR, Zhang T, Lee WR, Wu Y, Koontz BF, Armstrong AJ. Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. Eur Urol Oncol. 2020 Feb 13; doi: 10.1016/j.euo.2020.01.005. Epub 2020 Feb 13. PMID: 32063492.
Copy
Download .nbib